According to DataM Intelligence the global clinically isolated syndrome treatment market size was valued at USD 1 74 billion in 2025 and is projected to reach USD 3 55 billion by 2035 expanding at a CAGR of 7 4 during ... Press release - DataM Intelligence 4 Market Research LLP - Clinically Isolated Syndrome Treatment Market to Reach USD 3.55 Billion by 2035 as Early Risk-Based Treatment Gains Momentum - published on openPR.com ✓ In 2026, FDA regulatory materials continued identifying ocrelizumab as a therapy for relapsing forms of MS, which include clinically isolated syndrome, alongside relapsing-remitting and active secondary-progressive disease. ✓ In 2026, the FDA continued monitoring post-approval clinical evidence and safety requirements for neurological therapies, supporting ongoing evaluation of treatment options for relapsing MS populations that include CIS. Japan ✓ In August 2026, PMDA updated its clinical-trial information system, providing current information on ongoing Japanese drug-development programs relevant to neurological and other disease indications. BTK inhibitor development is adding another area of competition, while established injectable and oral therapies continue to serve patients according to indication, risk profile and physician preference. Get 20% complimentary customization within the report: https://www.datamintelligence.com/customize/clinically-isolated-syndrome-treatment-market?indhu Market Segmentation By Treatment Disease-modifying therapies led with an estimated 78% share, supported by their role in reducing the risk of disease activity and delaying progression toward multiple sclerosis in appropriate patients. Its strategy combines high-efficacy treatment with continued development of targeted therapies addressing relapsing and progressive disease mechanisms. Novartis Novartis participates in the MS market through therapies including Kesimpta and Mayzent while advancing remibrutinib. Its focus on B-cell-targeted and oral therapies strengthens its presence in evolving treatment pathways. Biogen Biogen maintains an established MS portfolio including interferon and oral therapies. Its long-standing clinical infrastructure and neurologist relationships support continued participation in early inflammatory demyelinating disease treatment.

Original title: “Clinically Isolated Syndrome Treatment Market to Reach USD 3.55 Billion by 2035 as Early Risk-Based Treatment Gains Momentum”

The Desmoid Tumors Clinical Trials analysis report delivers important insights into ongoing research of 4 pipeline Desmoid Tumors drugs clinical strategies upcoming therapeutics and commercial analysis Albany US September 27 2026 DelveInsight s Desmoid Tumors Pipeline Insight 2026 report provides ... Press release - ABNewswire - Desmoid Tumors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 4+ Leading Players Wheeling the Therapeutics Landscape - published on openPR.com The Cushing Syndrome Clinical Trials analysis report delivers important insights into ongoing research of 4+ pipeline Cushing Syndrome drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) September 27, 2026- DelveInsight's "Cushing Syndrome Pipeline Insight 2026" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Cushing Syndrome pipeline landscape. It covers the Cushing Syndrome Pipeline drug profiles, including clinical and nonclinical-stage products. It also covers the ... The Lyme Disease clinical trial analysis report delivers important insights into ongoing research of 7+ pipeline Lyme Disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Desmoid Tumors. The Desmoid Tumors Pipeline Report Provides Insights into * The report provides detailed insights about companies that are developing therapies for the treatment of Desmoid Tumors with aggregate therapies developed by each company for the same. It covers the Myositis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myositis therapeutics assessment by product ... The HABP Market focuses on the development, adoption, and commercialization of diagnostic solutions, antibiotics, and novel therapies for the management and treatment of hospital-acquired bacterial pneumonia (HABP), driven by the growing prevalence of healthcare-associated infections and increasing antimicrobial resistance.

Original title: “Desmoid Tumors Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 4+ Leading Players Wheeling the Therapeutics Landscape”

Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority. About Rezolute, Inc. Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials ... Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority. About Rezolute, Inc. Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating … (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026. ... upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumor HI, is ongoing. Notably, no assurance can be given that FDA will agree with the Company that there is evidence of clinically meaningful benefit observed in the sunRIZE study and accordingly the Agency could make the determination that the only path forward for the congenital HI indication is a new randomized control trial similar to sunRIZE.

Original title: “Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides ... | Bay to Bay News”

While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body dementia.

Original title: “Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward”

Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.

Original title: “Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge”

The U.S. Food and Drug Administration ... for the treatment of adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy on May 8, 2025. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial... The U.S. Food and Drug Administration (FDA) approved AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy on May 8, 2025. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Such forward-looking statements address various matters about, among other things, Verastem Oncology’s programs and product candidates, strategy, future plans and prospects, including statements related to the potential for and timing of commercialization of product candidates, the expected outcome and benefits of the Company’s collaboration with GenFleet Therapeutics (Shanghai), Inc., the timing of commencing and completing trials and compiling data, the Company’s proforma cash position, the expected timing of the presentation of data by the Company and the potential clinical value of various of the Company’s clinical trials. New external control arm analysis of avutometinib plus defactinib versus standard-of-care treatment for LGSOC will be presented during Poster Rounds · BOSTON--(BUSINESS WIRE)--$VSTM #CancerResearch--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that an abstract about molecular profiling and tumor biomarker analysis from the Phase 2 RAMP 201 clinical trial of avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC) has been selected for a late-breaking oral presentation at the International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting, taking place October 1–3, 2026, in Montreal, Canada.

Original title: “Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - BioSpace”

Kyverna Therapeutics' miv-cel showed improved mobility and a favorable safety profile at one year in patients with stiff person syndrome, further derisking an upcoming FDA application, William Blair said on Thursday. The biotech plans to file for priority review this year.

Original title: “Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data”

The weekly insulin Onswik will now be available to U.S. patients after initial approvals in Europe, Mexico and Japan.

Original title: “Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry”

Company prepares seamless transition into phase 2a development

Original title: “Heparegenix completes first darizmetinib treatment in phase 1b”

The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.

Original title: “Roche, Ionis RNA drug scores in kidney disease study”

After imeroprubart failed to demonstrate sufficient efficacy in lupus during a Phase 2b trial, Immunovant is moving on from the indication and looking to other high priority programs for the drug in neurology, endocrinology and rheumatology.

Original title: “Immunovant ditches lupus for multi-hyphenate inflammatory drug after mid-stage miss”

A late-stage test of Roche and Ionis Pharmaceuticals’ sefaxersen showed that the drug reduced protein in the urine, which suggests the RNA-targeting therapy could improve kidney function and delay transplant.

Original title: “Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod”